Edition:
United States

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

5.18USD
28 Apr 2017
Change (% chg)

$0.04 (+0.78%)
Prev Close
$5.14
Open
$5.10
Day's High
$5.18
Day's Low
$5.10
Volume
1,623
Avg. Vol
8,707
52-wk High
$6.28
52-wk Low
$2.80

Latest Key Developments (Source: Significant Developments)

Galmed Pharmaceuticals Q4 loss per share $0.40
Thursday, 23 Mar 2017 07:30am EDT 

Galmed Pharmaceuticals Ltd : Galmed Pharmaceuticals reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.40 . Q4 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S .Galmed Pharmaceuticals Ltd- cash and cash equivalents and marketable securities about $15.5 million as of Dec 31, 2016, versus about $23.0 million as of December 31, 2015.  Full Article

Galmed Pharmaceuticals signed agreement with University of California
Thursday, 22 Sep 2016 11:10am EDT 

Galmed Pharmaceuticals Ltd : Signed an investigator-initiated clinical trial agreement with University of California, San Diego, school of medicine .Artisan study is currently expected to be initiated in first half of 2017.  Full Article

Galmed Pharmaceuticals Q2 loss per share $0.39
Wednesday, 3 Aug 2016 08:00am EDT 

Galmed Pharmaceuticals Ltd : Q2 loss per share $0.39 .Expect that its cash balance will be sufficient to maintain its current operations through second half of 2017..  Full Article

Galmed and Samil Pharm sign deal for Aramchol(Tm) in Korea
Thursday, 28 Jul 2016 08:00am EDT 

Galmed Pharmaceuticals Ltd : Galmed Pharmaceuticals And Samil Pharm sign a license agreement for the commercialization of aramchol(tm) in Korea . Upon signing of agreement, samil will pay galmed an up-front fee of approximately $2.0 million .Samil has also agreed to pay additional clinical- and regulatory-based milestone payments, which may aggregate to $6.0 million.  Full Article

Galmed Pharmaceuticals says enters research collaboration agreement
Thursday, 30 Jun 2016 08:00am EDT 

Galmed Pharmaceuticals Ltd : Has right to enter into exclusive negotiations with Yeda to complete license agreement to commercialize diagnostic, prognostic tool for Aramchol .Galmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol(tm) effects on microbiome.  Full Article

Galmed Pharmaceuticals posts Q1 loss of $0.36 per share
Monday, 16 May 2016 08:27am EDT 

Galmed Pharmaceuticals Ltd : Galmed Pharmaceuticals reports first quarter 2016 financial results and provides business update . Q1 loss per share $0.36 .Q1 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Galmed Pharmaceuticals Q4 loss per share $0.40

* Galmed Pharmaceuticals reports fourth quarter and full year 2016 financial results